A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over ... inflammatory antibody it had licensed from a Chinese company. GSK acquired Aiolos months later ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

On January 2, US-based Lilly announced that its Mounjaro (tirzepatide), a dual-targeted ... "encouraging it to contribute more actively to the Chinese healthcare ecosystem." In 2024, Lilly ...

Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds, NICE said. It was found to be cost effective after data from the SURMOUNT-1 study reported that after 72 ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The company faced significant disruptions last year due to shortages of tirzepatide ... which would limit US funding of Chinese biotechnology suppliers, has yet to pass. The WuXi representative ...

Outside China, the tirzepatide products are known as Mounjaro ... that its placebo-controlled DREAMs-1 trial of mazdutide in Chinese adults with type 2 diabetes inadequately controlled by diet ...

The company’s recent success with its incretin portfolio, including tirzepatide and orforglipron ... particularly the potential for a Chinese invasion of Taiwan, which could lead to a global ...